.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB09_Lazertinib.Lazertinib

Information

Lazertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). It selectively targets both EGFR activating and T790M resistance mutations while sparing wild-type EGFR, thereby reducing off-target effects. Lazertinib is approved for clinical use in South Korea and has ongoing studies elsewhere.

Pharmacokinetics

Pharmacokinetic parameters reported for adult patients with advanced EGFR mutation-positive NSCLC following single and multiple oral dosing. The parameters are generally for healthy adults or cancer patients (no specific restrictions on age or sex).

References

1. Huh, KY, et al., & Yu, KS (2023). Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 175 112–120. DOI:10.1016/j.lungcan.2022.11.021 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36495784

Revisions

• 06/2025 initial generated model